H. Lundbeck, two new drug candidates in clinical phase I

Lundbeck has initiated phase I clinical studies of LU 31-130, a new antipsychotic for the treatment of psychosis, and LU AA-21-004, a new antidepressant for the treatment of depression. The objective of the phase I studies is to demonstrate the tolerability and pharmacokinetic profile of the drugs.